Chlamydia trachomatis infections demonstrate remarkable differences in clinical course that are approximately 40% based on host genetic variation. Here, we study the single nucleotide polymorphisms (SNPs) and their haplotypes in TLR2, TLR4 and TLR9 (TLR2 +2477G>A; TLR2 -16934T>A; TLR4+896A>G; TLR9 -1237T>C and TLR9 +2848G>A) in relation to the susceptibility to, and severity of C. trachomatis infections. We analysed the five SNPs in a cohort of 770 Dutch Caucasian women either attending a sexually transmitted diseases outpatient clinic (n = 731) or having complaints of subfertility (n = 39). Haplotype analyses showed a trend for TLR2 haplotype I (-16934T/+2477G) to protect against the development of symptoms and tubal pathology (P trend = 0.03) after Chlamydia infection. In the susceptibility cohort, TLR9 haplotype III (-1237C/+2848A) showed a significant decreasing trend in the development of symptoms after C. trachomatis infection (P = 0.02, OR: 0.55, 95%CI: 0.33-0.91). Logistic regression of the TLR2 haplotypes, TLR4+896A>G, and TLR9 haplotypes showed that the TLR2 haplotype Pathogens and Disease, 2016, Vol. 74, No. 1 combinations AG-TA and AG-TG confer risk (OR 3.4 (P = 0.01) and 1.6 (P = 0.03)), while the TLR9 haplotype combination TG-TA protects against C. trachomatis infections (OR: 0.4, P = 0.004). Our study shows that both TLR2 and TLR9 genes and SNP combinations do influence the clinical course of Chlamydia infections.
INTRODUCTION
The clinical course of Chlamydia trachomatis infection shows remarkable inter-individual differences in transmission, symptoms, persistence or clearance of infection, and development of late complications. This sexually transmitted infection (STI) is a major global health concern with approximately 100 million new cases arising every year (World Health Organization DoRHaR 2008) . Infections often have an asymptomatic clinical course and thus provide a huge reservoir for transmission. Identification of these cases by selective screening is difficult and associated costs have to be taken into account when screening programmes are considered (Morré et al. 2000; van Valkengoed et al. 2000) . Repeated infections seem associated with severe upper genital tract pathology including pelvic inflammatory disease (PID), ectopic pregnancy and tubal infertility in decreasing order of occurrence (Hillis et al. 1997) . Due to asymptomatic and subclinical C. trachomatis infection leading to unrecognized PID, many patients may stay untreated. This causes a deteriorated reproductive health of the society, and entails significant expenditures for the treatment of this pathology. Chlamydia trachomatis infections and other factors contribute to the 10%-15% subfertility observed in individuals (Evers, 2002) . Although other factors may cause fallopian tube damage, antibodies against C. trachomatis are consistently found in the serum of subfertile women with tuboperitoneal disorders (Evers, 2002) .
In general, the differences in clinical course could be explained by the interaction between host factors and virulence factors of the pathogen, and influenced by environmental factors such as co-infections. Chlamydia consists of different serovars (Molano et al. 2004; Morré et al. 1998) . No specific serovars have been identified that clearly link to the course of infection. However, the most prevalent isolates of serovars of the B serogroup were found to induce higher serologic responses than those of the less frequently isolated serogroups C and I (Verweij et al. 2009 (Verweij et al. , 2014 . The influence of bacterial factors on the course of infection is clear as was shown by the differences in duration and severity of infection between mice infected with serovars D, H and MoPn (Lyons et al. 2005 ). More recently, CT135 and CT144 have been described as a novel virulence factor for C. trachomatis infections, which might also be useful for post-infection sequelae (Jeffrey et al. 2010; Sturdevant et al. 2010) . However, since serovars and other bacterial factors do not fully explain the observed differences in clinical course, it is promising to study host immunogenetic variation in relation to Chlamydia infections. Recently it has been estimated, based on twin studies that up to 40% of the lymphoproliferative responses to C. trachomatis infections are based on host genetics (Bailey et al. 2009 ). New light has been shed on the clear differences in the clinical course of C. trachomatis infections, for the susceptibility to, and severity of (e.g. the development of late complications including infertility and tubal pathology (TP)) infection, prompting the field to elucidate genes involved in the observed differences in the course of infection.
Toll-like receptors (TLRs) form a major group of pattern recognition receptors (PPRs) which play an important role in the innate immune response to infections, serve as a link between innate and adaptive immunity, and are closely involved in pathogen recognition and host defence in infections including Chlamydia (Agrawal et al. 2011) . Chlamydiae express a variety of ligands that could serve as potential TLR ligands, leading to the production of cytokines and the formation of inflammasomes (Becker and O'Neill, 2007) .
In knockout mice studies, TLR2 plays an important role as a mediator in the innate immune response to C. trachomatis infection as well as in the early production of inflammatory mediators and in the development of chronic inflammatory pathology (Darville et al. 2003) . Functional SNPs in the TLR2 gene have been described in relation to infection and inflammation (Lorenz et al. 2000; Sutherland, Walley and Russell 2005) .
TLR4 has been described as a PPR for chlamydial lipopolysaccharide (LPS) via a receptor complex of CD14 and the accessory MD-2 (Poltorak et al. 1998) . Under certain circumstances, TLR4 signalling may be activated in the absence of CD14 and MD-2. Activation of TLR4 recruits myeloid differentiation protein 88 (MyD88), an intracytoplasmic downstream adaptor molecule, which activates inflammation, proliferation and apoptosis.
TLR9 is required for effective innate immune responses against bacterial pathogens. It is the receptor for bacterial DNA containing sequences of non-methylated CpG dinucleotides and is localized and acts in the cytoplasm. CpG DNA induces immunostimulation by inducing dendritic cell maturation, a strong T-helper-1-like inflammatory response, B-cell maturation and production of several cytokines (Bauer et al. 2001; Krieg et al. 1995; Klinman et al. 1996 Klinman et al. , 2004 Lundberg et al. 2003; Vollmer et al. 2004) . The TLR9 gene and its polymorphisms are associated with several (infectious) diseases such as pneumococcal infections (Albiger et al. 2007 ) and pouchitis (Lammers et al. 2005) .
TLR2, TLR4 and TLR9 employ similar proinflammatory pathways and are an example of the redundancy in pathogen recognition mechanisms. Therefore, we hypothesize that combined carriage of SNPs in these genes have a more severe impact on the immune system.
We have previously shown in murine models that SNPs in the TLR4 and TLR9 genes increase the risk of TP following C. trachomatis infections (den Hartog et al. 2009; Lyons et al. 2009 ). Furthermore, women with TP due to C. trachomatis infection are more often carriers of the mutant TLR4 +896G allele compared to those without TP (den Hartog et al. 2006) . Knockout mice deficient for TLR9, appear to be protected against reinfection with C. trachomatis ). Wildtype mice seem to be more protected against C. trachomatis reinfection compared to the TLR4-deficient mice (den Hartog et al. 2009 ). In a previous study, we found an association between TLR2 haplotype I and protection against development of TP ( Karimi et al. 2009 ). These results indicate the importance of these genes in C. trachomatis infections and warrant further study.
We extended our previously studied cohorts of STI and subfertile subjects with and without C. trachomatis to analyse the combined impact of variation in these genes and to strengthen our previously found associations. We aim to assess the role of combined genetic variation in these genes in relation to (i) the genetic susceptibility to (C. trachomatis positive vs. C. trachomatis negative), (ii) presence of symptoms and (iii) the severity (symptomatic vs. asymptomatic; TP vs. no TP) of C. trachomatis infections.
MATERIALS AND METHODS

Patient populations:
STI cohort A total number of 731 samples from a previous case-control study were used . The samples were derived from women of Dutch Caucasian (DC) origin, under the age of 33 (range 14-33 years; median 22 years) visiting the STI outpatient clinic of the Municipal Health Service in Amsterdam. Chlamydia trachomatis positive cases (n = 322) were defined as IgG antibody positive (Medac Diagnostika GmbH, Hamburg, Germany) and C. trachomatis DNA positive (Roche Diagnostics, Basel, Switzerland). Those without C. trachomatis infection with negative C. trachomatis-DNA test and negative C. trachomatis serology, served as controls (n = 409). Chlamydia trachomatis related symptoms include increased vaginal discharge, perand postcoital blood loss, lower abdominal pain not related to menses or gastrointestinal problems, and/or dysuria. Informed consent was obtained in the case-control study .
Laboratory tests
Chlamydia trachomatis detection and extraction of DNA was described elsewhere . In short, a cervical swab was obtained for the detection of C. trachomatis-DNA by PCR (van Doornum et al. 2001) . Peripheral venous blood was collected for the analysis of IgG antibodies against C. trachomatis (Medac Diagnostika GmbH, Hamburg, Germany). A titre of ≥1:50 was considered positive. Testing for coinfections (i.e. Candida albicans, Neisseria gonorrhoea, Trichomonas vaginali, and Herpes simplex virus 1/2) was performed as described previously .
Subfertility cohort
A total number of 39 samples derived from DC women were selected from a large cohort (n = 259). These women visited the department of Obstetrics and Gynaecology of the Academic Hospital Maastricht, The Netherlands, in the period between December 1990 and November 2000 because of subfertility (Land et al. 2003) . Out of the 39 women, 26 were diagnosed with clinically well-defined TP based on stringent criteria in order to compare development of TP in C. trachomatis IgG positive women in relation to host genetic factors.
A laparoscopy with tubal testing had been performed in these women as part of their fertility work-up. Preoperative blood was obtained from all patients for Chlamydia IgG antibody testing (CAT), and spare sera were cryopreserved. Two independent investigators, who were unaware of the CAT results, scored the laparoscopy reports to assess the grade of TP. TP was defined as extensive peri-adnexal adhesions and/or distal occlusion of at least one tube at laparoscopy (Land, Evers and Goossens 1998) . Subfertile women without peri-adnexal adhesions and had patent tubes at laparoscopy served as negative controls.
IgG antibodies to C. trachomatis were detected with a speciesspecific MIF test (AniLabSystems, Finland), as described previously by Land et al. (2003) , with comparable sensitivity and specificity as compared to the IgG ELISA from Medac used for the STI cohort (van Valkengoed et al. 2002) . A positive C. trachomatis IgG MIF test was defined as a titre ≥1:32. Fig. 1 shows a flowchart summarizing in-and exclusion criteria of the two groups. 
IMMUNOGENETIC ANALYSES
DNA Extraction
STI cohort
Eukaryotic DNA from PBMC was isolated using the isopropanol isolation method. In short: 100 μl PBMC in PBS were added to 600 μl L6 (Nuclisens Lysisbuffer, Organon Teknika, Boxtel, The Netherlands) and 1 μl glycogen (Roche Molecular Diagnostics, Almere, The Netherlands). The samples were incubated for 30 minutes at 65
• C and left to cool at RT. An equal volume of cold (-20 • C) isopropanol was added to the samples. The samples were then centrifuged (20 min at 20.000 g). The supernatant was discarded and the pellets were washed twice in 75% EtOH. The pellets were dissolved in T10 overnight at 4
• C and then stored at -20
• C until further analysis.
Subfertility cohort
Genomic DNA was extracted out of the 200 microliter cryopreserved sera using the High Pure PCR Template Preparation Kit (HPPTP kit; Roche Molecular Biochemicals, Mannheim, Germany).
Gene polymorphisms
Genotyping was performed using the TaqMan method (Applied Biosystems). We genotyped the following SNPs: TLR2 +2477 G>A, Arg753Gln (rs5743708) and TLR2 −16934 T>A (rs4696480); TLR4 +896 A>G, Asp299Gly (rs4986790); TLR9 −1237 T>C (rs5743836) and TLR9 +2848 G>A, Pro545Pro (rs352140). The two TLR9 SNPs are used to tag the four haplotypes as described by Lazarus et al. (2003) . TLR2 −16934 has been described as a tagging SNP and divides the 11 SNP haplotype in two clades (Sutherland, Walley and Russell 2005) . TLR2 +2477 is used to further differentiate the haplotypes.
Statistical analyses
Observed genotypes were tested for deviations from the Hardy-Weinberg equilibrium. Fisher exact or χ 2 tests were used to test for differences in TLR2, TLR4 and TLR9 haplotypes/genotypes/carrier frequencies between the (sub) groups. P-values <0.05 were considered statistically significant. TLR2 and TLR9 haplotypes were inferred using PHASE v2.1.1 and SNPHAP (Stephens, Smith and Donnelly 2001; David 2002; Stephens and Donnelly 2003) . We modelled combined carriage of SNPs using backward stepwise logistic regression on the TLR2 haplotypes, TLR4+896 A>G and TLR9 haplotypes with C. trachomatis susceptibility (C. trachomatis positive vs. C. trachomatis negative) as the outcome variable. Analyses were performed with SPSS 15 (SPSS Inc., Chicago, Illinois).
RESULTS
Distribution of genotypes
The overall genotype distributions of the TLR2 −16934 T>A, TLR2 +2477 G>A, TLR4 +896 A>G, TLR9 −1237 T>C and TLR9 +2848 G>A SNPs are shown in Tables 1a-c, respectively. TLR2 and TLR9 haplotype distributions are shown in Tables 2a and 2b , respectively. We analysed the effect of host genetics on the development of TP and symptoms. Chlamydia trachomatis positive patients with TP were more frequently carriers of the TLR2 +2477 * A allele than patients without TP (19.2% vs. 0%; P = 0.015; OR 17.5; 95% CI 0.9-343). Chlamydia trachomatis positive patients carrying TLR9 −1237 CC are more frequently asymptomatic (5.2%) than symptomatic (0.8%) (P = 0.056; OR: 0.14; 95% CI: 0.02-1.12) (Table 1c). On the genotype, mutant allele carriage, and haplotype level, the analysed SNPs showed no statistical significance for susceptibility to C. trachomatis infections.
Trend analyses in C. trachomatis positive patients (asymptomatic > symptomatic > TP) show that TLR2 haplotype I (-16934 T / +2477 G) protects against a more severe clinical course of infection, i.e. TP (P trend = 0.03; χ 2 trend : 4.6) ( Table 2a) . TLR9 haplotype III (-1237C / +2848A) is less frequent in C. trachomatis symptomatic patients compared to C. trachomatis asymptomatic patients (P = 0.02; OR: 0.55; 95% CI: 0.33-0.91) (Table 2b) .
Logistic regression of the TLR2 haplotypes, TLR4 +896 A>G, and TLR9 haplotypes shows that the TLR2 haplotype combinations AG-TA and AG-TG, and the TLR9 haplotype combination TG-TA affect the susceptibility to C. trachomatis infections. The TLR2 haplotype combinations increase the risk of C. trachomatis infections (II -III (AG-TA): P = 0.01; OR: 3.4; 95% CI 1.28 -9.07 and II -I (AG-TG): P = 0.03; OR: 1.6; 95% CI 1.06-2.38, respectively), while TLR9 haplotype combination I -II (TG-TA) decreases susceptibility to C. trachomatis infections (P = 0.004; OR: 0.4; 95% CI 0.21-0.74). TLR4 was automatically removed from the model during the backward stepwise logistic regression, due to the lack of a significant effect in the model. 
DISCUSSION
This study shows evidence that TLRs are closely involved in pathogen recognition and host defence in C. trachomatis infections and that host genetic factors contribute to the pathogenesis as well as to the course and severity of this infection.
Although single SNP analyses showed no significant differences in distribution among the STI cohort, logistic regression modelling of the effect of TLR4, TLR2 haplotypes and TLR9 haplotypes showed significant effects of specific combinations of TLR2 and TLR9 haplotypes. TLR2 haplotype combinations -16934A/+2477G to -16934T/+2477A and −16934A/+2477G to -16934T/+2477G (Table 2a) show an increased Chlamydia susceptibility. In both haplotype combinations, the samples are heterozygous for the -16934 SNP (TA), and either heterozygous (GA) or homozygous (GG) for the +2477 SNP. The haplotype combination containing the +2477 heterozygote (-16934A/+2477G to -16934T/+2477A) has a higher risk (OR: 3.4) compared to the other haplotype combination (OR: 1.6). Also, TLR2 +2477 * A was more frequently present in patients with TP as compared to women without TP (Table 1a) . In this study, a significant trend was observed for TLR2 haplotype I (-16934 T / +2477 G) in the protection against development of symptoms and subsequent development of TP. These results corroborate our previous findings in a much smaller study where we have shown that TLR2 haplotype I protects against development of TP (Karimi et al. 2009 ).
We did not observe significant differences in the TLR4 genotype distributions between the cases and controls in this study in both STI and TP cohorts; although in a previous study we found a trend for the development of TP in C. trachomatis DNA positive and C. trachomatis IgG positive women (den Hartog et al. 2009 ) as compared to C. trachomatis DNA negative and IgG negative women. Murine studies do show a role for TLR4 in Chlamydial infections, although human studies (including this study) indicate that the role of TLR4 in human Chlamydia infections might be modest (den Hartog et al. 2009) . A recent study, however, did show a role for a TLR4 SNP. This SNP (rs1927911) is located in an intron and the mutant genotype CC was associated with increased risk of Chlamydia infection in an African American population (Taylor et al. 2012) . Although the precise role of this SNP is unknown, the authors suggest it may be in linkage disequilibrium with another functional SNP.
Chlamydia trachomatis positive patients carrying TLR9 −1237 CC (Table 1c) are less frequently symptomatic (P = 0.056; OR: 0.14, 95% CI: 0.02-1.12).
* * With regard to the presence of symptoms, the analysed SNPs showed no statistical significant differences among the different groups in the genotype. Haplotype analyses have shown that haplotype I (-16934 T / +2477 G) (Table 2b ) protects against development of symptoms and TP. The -16934 T allele and the +2477 G allele are present in the most protective combinations, while the -16934 A allele and the +2477A allele are present in the risk combinations, suggesting that the investigated TLR2 alleles have an effect on the immune response to C. trachomatis.
In the subfertility cohort, TLR9 haplotype III (-1237 C / +2848 A) shows a decreasing trend in the development of symptoms (P = 0.020; OR: 0.55; 95% CI: 0.33-0.91) (Table 2b) . We have previously observed a decreasing trend in the carriage of haplotype IV (-1237 C / +2848 G) in C. trachomatis positive women without symptoms, with symptoms, and with TP ). Both haplotypes contain the TLR9 −1237 C allele, suggesting a potential role for this allele in the protection against Chlamydia infections.
Our results are partially corroborated by different previous studies describing the importance of TLR2 in the recognition of C. pneumoniae, LPS-signalling, and the development of murine TP (Darville et al. 2003; Prebeck et al. 2001; den Hartog et al. 2009; Erridge et al. 2004) . TLR2 deficient mice were found to have significantly lower levels of inflammatory mediators in genital tract secretions during the first week of infection, and there was a significant reduction in oviduct and mesosalpinx pathology at late time points (Darville et al. 2003) . This suggested that TLR2 was the predominant receptor involved in the detection of and inflammatory response to C. trachomatis in the genital tract. However, Dong and colleagues did not find a significant role for TLR2 signalling in mice infected with C. muridarum, where they used hydrosalpinx as hallmark for TP (Dong et al. 2014) . Furthermore, TLR2 was described to be tightly associated with the bacteria during the intracellular phase, and that it was recruited to the inclusion membrane together with MyD88. Hereby, intracellular TLR2 was suggested to be responsible for the initiation of signal transduction events during infection with C. trachomatis (O'Connell et al. 2006) .
The study of Lorenz et al. (2000) * * * shows that the +2477 mutant is less responsive to lipoproteins, and the studies of Ogus et al. (2004) and Bochud, Hawn and Aderem (2003) show increased susceptibility to tuberculosis 2477 * A carriers. One might hypothesize that inadequate recognition of Chlamydia in TLR2 +2477 * A carriers results in increased susceptibility and severity of Chlamydia infections. TLR9 haplotype combination -1237T/+2848G to -1237C/+2848G reduces susceptibility to Chlamydia infections (OR: 0.4). This combination contains the TLR9 −1237 C allele which is also present in haplotypes III and IV, as described above. Ng et al. (2010) used in silico analyses to demonstrate potential differences in NFκB binding affinity between the T and C alleles. They used luciferase and binding assays to demonstrate that the C allele has a higher NFκB binding affinity and results in increased expression of TLR9. One might hypothesize that the increased TLR9 expression in TLR9 −1237 * C carriers increases recognition of Chlamydia that results in a reduction of symptoms and late complications of Chlamydia infections as observed in our studies and literature. Our results contribute to the understanding of disease pathogenesis of C. trachomatis infection, and our findings provide new insights into the immunological pathways which may contribute to the heterogeneity of the infection. These results can be integrated with existing immunogenetic knowledge, possibly assisting in progression to targeted and personalized approaches in prevention, diagnosis and treatment of the infection.
This study shows that TLR2 and TLR9 influence the clinical course of Chlamydia infections. Specific TLR2 and TLR9 haplotypes protect against a more severe clinical course of infection. Alterations in TLR2 function and NFκB binding in TLR9 may explain the association between the genetic variation and the observed differences in Chlamydia infections. We did not observe a significant effect for TLR4 in this study. This study provides further evidence for the effect of host genetic variation on Chlamydia infections, and extends our knowledge of the immune system. This may help us define better diagnostic and therapeutic methods in the future. 
